Imatinib Mesylate Tablet, Film Coated
Product Images NDC 62135-658

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 62135-658). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chartwell Rx, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Imatinib Mesylate 100mg Bottle Label)

FDA Label Image

Image Description (Imatinib Mesylate 400mg Bottle Label)

FDA Label Image

Image Description (Imatinib Mesylate Graph 1)

Image Description (Imatinib Mesylate Graph 1)
This document appears to be a table illustrating the results of a study involving patients taking Imatinib Mesylate Tablets and IFNsAC. The data includes the number of patients with progression, the number of patients censored at discontinuation or last follow-up, hazard ratio with confidence intervals, and the Log-rank test result. The information is presented over a period of months since randomization.*
FDA Label Image

Image Description (Imatinib Mesylate Graph 2)

Image Description (Imatinib Mesylate Graph 2)
This section of text appears to contain statistical data related to the progression of patients to accelerated phase (AP) or blast crisis (BC) while on treatment with Imatinib Mesylate tablets and IFN+AraC. The hazard ratio and logrank test results are provided, along with the number of patients at risk over a period of months since randomization. It seems to be a part of a clinical study or trial evaluation.*
FDA Label Image

Image Description (Imatinib Mesylate Graph 3)

FDA Label Image

Image Description (Imatinib Mesylate Graph 4)

Image Description (Imatinib Mesylate Graph 4)
This text provides data on the recurrence-free survival in Study 2, with details on event survival time in months. The figure shows values and the probability of recurrence-free survival over time for the ITT population.*
FDA Label Image

Image Description (Imatinib Mesylate Graph 5)

Image Description (Imatinib Mesylate Graph 5)
Not available.*
FDA Label Image

Image Description (Imatinib Mesylate Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.